Physician profile
Adam Howard
NPI 1679712624
$5,424.39
in general payments reported to CMS, 2019-2025
35 companies · $734 in 2025
The $734 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,570 · 2020: $831 · 2021: $317 · 2022: $800 · 2023: $839 · 2024: $333 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,781 · Travel and Lodging: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,781.40 |
| Travel and Lodging | $124.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $944.13 | 2019-2025 | Grafix, Stravix, Collagenase Santyl |
| Integra Lifesciences Corporation | $543.57 | 2019-2020 | |
| Zimmer Biomet Holdings, INC. | $344.33 | 2019-2023 | Tapestry, Medline Industries, INC., Stratum Foot Plating System |
| Medical Device Business Services, INC. | $338.86 | 2019 | |
| Amgen INC. | $337.54 | 2024-2025 | Krystexxa |
| Biotissue Holdings INC. | $284.03 | 2022-2024 | |
| Organogenesis INC. | $249.53 | 2021-2023 | Puraply |
| Musculoskeletal Transplant Foundation INC. | $238.84 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $238.76 | 2020-2025 | Nuzyra |
| Nevro Corp. | $194.16 | 2023 | Senza |
| Stryker Corporation | $191.87 | 2023-2025 | Ortholoc 2 Lapifuse, Prostep, Prostep Mica |
| Linvatec Corporation | $170.88 | 2023 | Fracture and Correction Colag 2, Colink Plating System, Colink 2 |
| Horizon Therapeutics Plc | $164.74 | 2019-2020 | |
| Alafair Biosciences, INC. | $149.20 | 2024 | Versawrap |
| Wright Medical Technology, INC. | $131.34 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paragon 28, INC. | $120.37 | 2019-2023 | Mtp |
| Depuy Synthes Sales INC. | $113.60 | 2019 | |
| Osiris Therapeutics INC. | $100.36 | 2019 | |
| Averitas Pharma INC. | $91.93 | 2023-2024 | Qutenza |
| Fidia Pharma USA INC. | $61.85 | 2019-2020 | |
| Arthrosurface Incorporated | $58.57 | 2019 | |
| Evolution Surgical, INC | $55.63 | 2019 | |
| Bioventus LLC | $31.30 | 2025 | Exogen Ultrasound Bone Healing System |
| Acell, INC. | $30.46 | 2020 | |
| Mimedx Group, INC. | $27.39 | 2025 | |
| Access Pro Medical, LLC | $27.05 | 2025 | Matriderm |
| Tactile Systems Technology INC | $26.36 | 2024 | Entre Plus, Flexitouch Plus |
| Amniox Medical, INC. | $24.53 | 2020 | |
| Alfasigma USA, INC. | $23.68 | 2021 | |
| Gramercy Extremity Orthopedics LLC | $20.58 | 2021 | |
| Zyla Life Sciences, INC. | $19.84 | 2019 | |
| Ossio INC | $19.55 | 2023 | |
| Orthofix Medical, INC. | $17.92 | 2025 | Physio-Stim |
| Treace Medical Concepts, INC. | $16.44 | 2025 | |
| Grt US Holding, INC. | $15.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.